CHINA

 
Soaring demand for Infant Formula containing OPO in China

There is growing demand for infant formula containing OPO in China, according to Advanced Lipids, one of the major suppliers of the ingredient.
OPO, also known as SN-2 palmitate, is a premium quality ingredient that mimics the fatty acid profile of human breast milk. Demand for infant formula containing OPO has soared over the past decade. In 2007, there were only 5 brands containing INFAT®, Advanced Lipids’ OPO product. Now, there are over 150.
OPO is particularly sought after in China, which accounts for almost 40% of the retail value of the US$48 billion global formula market. Advanced Lipids will showcase OPO and its growing body of clinical research supporting the growth in demand for OPO in China, during Food Ingredients China which will be held from 22 to 24 March in Shanghai.
Dr Sigalit Zchut, Advanced Lipids’ Chief Scientist, will present the results of a recent pre-clinical study showing that INFAT® may have a beneficial effect on the length and quality of bones. In addition, INFAT® also offers many other clinically proven benefits like longer sleep duration, reduced crying, and better fat and calcium absorption.
Dr Sigalit added, “Quality is extremely important in China’s formula market where the 2 biggest factors driving choice of product are nutritional value and safety. Consumers actively seek out formula that contains OPO, which they know offers many benefits that are substantiated by clinical studies. The more we have learned about the clinical benefits of OPO, the more demand has risen in China. At Advanced Lipids, we are leading much of the scientific research and innovation contributing to the success of OPO.”
The recent relaxation of China’s single child policy allowing some Chinese to have up to 2 babies, has sparked a mini baby boom, which will accelerate further growth in premium quality formula ingredients in the country. This growth will be further supported by new regulations which emphasise on higher quality for milk products.
Advanced Lipids is a joint venture established by Enzymotec, a member of the Frutarom group and a leading biotech company specialising in lipid-based bio-functional ingredients; and AAK, a global producer and supplier of speciality vegetable fats and oils for the infant formula industry. Combining Enzymotec’s clinical and chemical expertise in lipid technologies with AAK’s international strength in food safety, production and logistics, Advanced Lipids offers a unique package of clinical research, development, flexible blending, quality and logistics.
To find out more, click to www.advancedlipids.com.